Mechanism of Action
MDM2/MDMX Dual Inhibition
ALRN-6924 is derived from the p53 transactivation domain helix and is stabilized by an all-hydrocarbon staple that locks it in an alpha-helical conformation. This conformation allows high-affinity binding to both MDM2 and MDMX, the two proteins that normally bind the p53 helix and target it for proteasomal degradation. Dual inhibition simultaneously releases p53 from both degradation pathways, more completely restoring its tumor suppressor activity than single-target MDM2 inhibitors.
Cell Penetration via Stapling
The hydrocarbon staple serves dual purposes: it locks the alpha-helical conformation for high-affinity target binding and confers cell membrane permeability to the peptide. Unlike unstapled p53-derived peptides that cannot enter cells, ALRN-6924 efficiently penetrates cell membranes through a non-endosomal pathway, reaching the nucleus where MDM2 and MDMX exert their suppressive effects.
Research Summary
AML and MDS
Phase 2Phase 1/2 trials in acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) showed single-agent activity with an objective response rate of approximately 17% in relapsed/refractory AML. p53 pathway activation biomarkers correlated with response, validating the mechanistic approach. Combination with azacitidine is being explored.
Chemotherapy Sensitization
Phase 1ALRN-6924 was also investigated as a transient p53 activator in normal cells to protect them from chemotherapy toxicity. By temporarily inducing cell cycle arrest in normal cells via p53 activation, ALRN-6924 reduces DNA damage in healthy tissue while tumors with p53 mutations remain sensitive to chemotherapy.
Calculate your ALRN-6924 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| AML/MDS treatment | 3.1 mg/kg | Weekly (Days 1, 8, 15) | IV infusion over 1 hour |
| Chemosensitization | 1.5 mg/kg (before chemo) | Per cycle | IV infusion |
Clinical trial use only. Biomarker selection (TP53 wild-type) required for enrollment.
Interactions
Safety Profile
Common adverse effects include gastrointestinal toxicity (nausea, vomiting), hematologic effects (thrombocytopenia, neutropenia), and QTc prolongation. On-target toxicity from p53 activation in normal tissues contributes to bone marrow suppression. Dose-limiting toxicities observed in Phase 1 include thrombocytopenia and QTc prolongation. Careful cardiac monitoring is required during treatment.
References
- [1]Carvajal LA et al. (2018). Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. Science Translational Medicine, 10(436), eaao5234.
- [2]Graves B et al. (2012). Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. PNAS, 109(29), 11788-11793.